Florian Brand

Co-Founder and ex-CEO of @AtaiBeckley NASDAQ : $ATAI. Passionate about building companies, mental health and biotech. Views are my own. No investment advice.

[Florian Brand @flobrand]

@gjurvetson @POTUS @SecKennedy @calleymeans @w_bryan_hubbard @FutureJurvetson Incredible accomplishment for the millions that live without the access to care that they deserve! Congrats @gjurvetson!!! Grateful for your leadership 🙏🙏🙏

[Florian Brand @flobrand]

@PsychedVantage well said, Jake!

[Florian Brand @flobrand]

This is so huge!! It cannot be emphasized enough what this policy paradigm shift means for people living with mental health conditions for whom available treatment options don’t work!

Congrats and an enormous amount of credit to @FutureJurvetson and @gjurvetson for spearheading this important policy initiative! Your grid and tenacity in advocating for this long overdue policy change is truly remarkable !

[Steve Jurvetson @FutureJurvetson]

🏛️ Historic moment in the Oval Office just now for advancing psychedelic cures for the mental health crisis.

“The Prohibition on Psychedelics is now over.” — Bryan Hubbard

Funniest quip: “Ibogaine, can I get some?” — POTUS

With a chorus of support from leaders I photographed here, L to R: heads of NIDA, NIH, (Joe Rogan), HHS, White House Advisor Calley Means, FDA, and Genevieve who had been working on this for years.

Expect three accelerated programs for FDA approval next week, VA studies and Federal funding, and a hope for CMS reimbursement by end of year.

Full text: https://t.co/LjT3r4Qq6q

[Florian Brand @flobrand]

@FutureJurvetson @w_bryan_hubbard @gjurvetson @DrOz @DrMakaryFDA @calleymeans @RobertKennedyJr @POTUS @joerogan 👏👏👏

[Christian Angermayer @C_Angermayer]

I am a strong believer in ibogaine, which is one of the reasons why @ataibeckley acquired the residual interest in its ibogaine program in Q4 2023 and now owns it 100%.

I’m very encouraged to see the administration taking a positive public stance on this important topic.

Ibogaine and other psychedelic therapies deserve greater attention - I believe they have the potential to improve the lives of millions.

And I believe $ATAI will lead this paradigm shift.

https://t.co/rIsQTkMCSB

[Florian Brand @flobrand]

@aakashgupta @grok - how did Golf rank?

[Florian Brand @flobrand]

6/6
That is the real opportunity now.

Not just proving these treatments can work, but building the system that can deliver them responsibly and at scale to patients in need.

Looking forward to the conversation at @START_Global Summit on Friday.

[Florian Brand @flobrand]

2/6 Why now?

Because this is no longer just an interesting scientific idea. It is becoming a real healthcare category.

The unmet need in mental health remains enormous, and the field is entering a critical phase.

[Florian Brand @flobrand]

5/6 But approvals alone will not be enough.

To bring this new model of care to patients at scale, especially in Europe, it will take an ecosystem: founders, scientists, clinicians, regulators, payors, care providers, and investors working together.

[Florian Brand @flobrand]

1/6 Excited to join @START_Global this week in Switzerland for a fireside chat on the psychedelic medicine opportunity.

As co-founder and former CEO of one of the first psychedelics-focused biotechs, I’ve had a front-row seat to this field’s move from stigma to serious science, credible companies, and real clinical momentum.

$ATAI $CMPS $GHRS $DFTX

[Genevieve Jurvetson @gjurvetson]

Check out this incredible pilot study on smoking that was just published in JAMA.

Psilocybin-assisted therapy helped smokers quit at far higher rates than the nicotine patch.

At 6 months, participants receiving psilocybin had over 6X greater odds of prolonged abstinence.

Psychedelics may become one of our most powerful tools for treating addiction!

[Florian Brand @flobrand]

https://t.co/ybrHaL5y9L

[Florian Brand @flobrand]

1/ When @LarsWilde and I flagged increasing pharma interest in psychedelics as a very encouraging sign last year, some thought it was premature. Turns out it wasn’t. A thread 🧵

$ATAI $CMPS $DFTX $GHRS

[Florian Brand @flobrand]

11/ In our substack we also discussed which Big Pharma could become the second-mover after AbbVie, focusing on players with existing commercial-stage CNS franchises. Since then we heard at events in Boston and SF that Eli Lilly, which recently re-entered CNS, is showing interest also.

Links in reply below 👇

[Florian Brand @flobrand]

https://t.co/GLg8Sg1xNx